Genetics of QT Prolongation With Antiarrhythmics

UnknownOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 31, 2022

Study Completion Date

April 30, 2023

Conditions
Long QT SyndromeDrug Toxicity
Interventions
DRUG

Dofetilide and/or sotalol

This is an observational study of patients receiving Dofetilide and/or sotalol as part of their routine clinical care. Patients receiving either of these medications will be compared with population controls for genetic analysis.

Trial Locations (5)

44195

RECRUITING

Cleveland Clinic, Cleveland

55902

RECRUITING

Mayo Clinic, Rochester

80045

RECRUITING

University of Colorado Hospital, Aurora

02114

RECRUITING

Massachusetts General Hospital, Boston

02215

COMPLETED

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mayo Clinic

OTHER

collaborator

The Cleveland Clinic

OTHER

collaborator

University of Colorado, Denver

OTHER

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Massachusetts General Hospital

OTHER